Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | DRD3 | P35462 | 5/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4669159 | 0.86 | KCNH2 (0.49) | KCNH2HRH1HRH2 | |
| SCHEMBL4505273 | 0.86 | HRH1 (0.37) | KCNH2HTR1ADRD4HTR2AHRH1 | |
| SCHEMBL2967590 | 0.85 | KCNH2 (0.44) | KCNH2GPBAR1CD274HTR1ADRD4 | |
| SCHEMBL4513667 | 0.85 | OPRM1 (0.40) | KCNH2HTR1ADRD4HTR2AHRH1 | |
| SCHEMBL5533435 | 0.85 | KCNH2 (0.38) | KCNH2GPBAR1CD274HTR1ADRD4 | |
| Hydrochloric Acid SCHEMBL4521680 | 0.85 | KCNH2 (0.36) | KCNH2HTR1ADRD4HTR2AHRH1 | |
| SCHEMBL4512005 | 0.85 | KCNH2 (0.36) | KCNH2HTR1ADRD4HTR2AHRH1 | |
| SCHEMBL4125747 | 0.84 | KCNH2 (0.48) | KCNH2GPBAR1CD274DRD2DRD3 | |
| SCHEMBL4523088 | 0.83 | KCNH2 (0.37) | KCNH2HTR1ADRD4HTR2AHRH1 | |
| SCHEMBL5533438 | 0.83 | HTR1A (0.38) | KCNH2HTR1ADRD4HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354917-B2 | Oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | claimed |
| US-20070259864-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20080207899-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7354917-B2 | Oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-20070259864-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207899-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 14/4885GPBAR1 820/4885CD274 1922/4885 |
| US-20070259864-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 14/4885GPBAR1 820/4885CD274 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.